The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for people w/o native Ab response —Time of symptom onset does not correlate w/ Ab response https://t.co/itwnZp2GzZ https://t.co/JOfiJyQgI4
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Dec 2020 – Dec 2024Where it's discussed
-
X / Twitter267 posts
-
News90 articles
-
Blogs15 articles
-
Facebook10 posts
-
Reddit4 posts
-
YouTube3 videos
-
Bluesky1 posts
AI synopsis
What people are saying
Many discussions reference the study's conclusions, such as 'the REGN-COV2 antibody cocktail reduced viral load, particularly in those without previous antibody responses.' Participants are eager to compare this treatment with others, noting comparisons with Paxlovid and Molnupiravir, highlighting the research's relevance. The tone is generally informative, with phrases like 'promising results' and 'significant implications,' helping to foster a sense of urgency and interest in the subject matter.
The bulk of discussions express a moderate level of support for REGN-COV2's conclusions regarding its efficacy.
Posters display a high level of curiosity, often referencing details from the publication and comparing it with other Covid-19 treatments.
Participants are moderately engaged, discussing specific results and implications, but some posts show dismissive attitudes towards opposing views.
Many believe the findings have significant implications for outpatient Covid-19 treatment, suggesting they could change approaches to managing the disease.
Abstract in brief
- REGN-COV2 is a cocktail of two neutralizing monoclonal antibodies designed to combat Covid-19 in nonhospitalized patients, with a focus on reducing viral loads and the risk of treatment-resistant mutations.
- In a trial involving 275 patients, those receiving REGN-COV2 showed a significant reduction in viral load compared to the placebo, particularly in patients who were initially serum antibody-negative.
- Adverse reactions were similar in both REGN-COV2 and placebo groups, indicating that the treatment was relatively safe for patients.
Top posts
Most liked on X and Bluesky→抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/K3bNhCZxdp
新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていません。https://t.co/lAMZeviB2U
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #VisualAbstract by @hellokidneyMD
2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/znEhmakdeF
Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated with mAbs, viral load also dropped significantly by 7 days in both study arms. Viral load appears to be highest at symptom onset. https://t.co/vIKJvz7XjA
All mentions
Monoclonal Antibodies - What you NEED to know!
Outpatient COVID-19 Treatments: Efficacy of Monoclonal Antibodies
Dr. Christy discusses outpatient treatment options for COVID-19, focusing on REGN-COV2, a cocktail of two neutralizing monoclonal antibodies. This treatment has shown significant viral load reduction in nonhospitalized…
Analysis of COVID-19 Antibody Treatment and Its Impacts
In this video, we analyze REGN-COV2, a cocktail of neutralizing antibodies aimed at combating Covid-19 in outpatients. The treatment demonstrated significant viral load reduction in patients. We explore its safety…
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | New England Journal of Medicine https://t.co/y1MDxiYNBf
@ShteinMichael https://t.co/wPRXhl4OEs https://t.co/lX9KAEZsyH
RT @sudokuvariante: Voici quelques points de comparaison avec le paxlovid, le molnupiravir, et certains anticorps monoclonaux. Données des…
RT @sudokuvariante: Voici quelques points de comparaison avec le paxlovid, le molnupiravir, et certains anticorps monoclonaux. Données des…
RT @sudokuvariante: Voici quelques points de comparaison avec le paxlovid, le molnupiravir, et certains anticorps monoclonaux. Données des…
Voici quelques points de comparaison avec le paxlovid, le molnupiravir, et certains anticorps monoclonaux. Données des études: https://t.co/Zt9XqvB2ws https://t.co/O4YxHPARaj https://t.co/7gwYGNm8Xn https://t.co/amAJWK2dkJ 6/n https://t.co/YlACj3PYQV
Delete my tweet by mistake... Ivermectin (Chaccour) Paxlovid (Hammond) Regeneron (Weinreich, Table S2) https://t.co/amAJWK2dkJ https://t.co/QRrJS6sXER
Got COVID? Watch this for outpatient treatment options available in 2022 https://t.co/dmmq5MyhLn via @YouTube
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/Q3o8SDcMOS
@Minkiemom17 @chuha @Tangento In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load https://t.co/Hibb7oBinl
@galswguitars202 @NikkiFried Wrong again. https://t.co/4XkKSKr6Ph
Got COVID? Watch this for outpatient treatment options available in 2022 https://t.co/JwnWbZ6IxJ via @YouTube
Got COVID? Watch this for outpatient treatment options available in 2022 https://t.co/cU1sgYQtBy via @YouTube
@Buscusriot @PeterMcCormack @Timcast https://t.co/wJ4nTGcgiQ https://t.co/W7WMy3H2ij https://t.co/sPXcdi7Jsg https://t.co/MkDeW0gsFy. Study (but don't trust) the science bro
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/rvhgsuFpj6
Monoclonal Antibodies - What you NEED to know! https://t.co/SPhXLShm9b via @YouTube
Got COVID? Watch this for outpatient treatment options available in 2022 https://t.co/niOLDtd7Fk @YouTubeより
@KenWarnock @DrLeanaWen The source is the source is 5:20 of this video, from Dr Christy Risinger: https://t.co/eUdoDNLHTP She is also for vaccines. @chrismartenson, a PhD epidemiologist, highlighted ivermectin’s effectiveness well before the first “COVID vaccines”. The problem is willfull ignorance.
https://t.co/smGbBkd1Ly
Monoclonal Antibodies - What you NEED to know! https://t.co/0IABxBQX0j via @YouTube
@roseyx8 @KGJ26 @TimMalia Monoclonal: https://t.co/uHXR3eKCpZ Vaccination: https://t.co/mo3t0zSBOM https://t.co/du1aDuLYUE https://t.co/Ndt61lSyKm
Also available to PREVENT COVID IF EXPOSED! Monoclonal Antibodies - What you NEED to know! https://t.co/U98TwmSFv2 via @YouTube
@ABsteward @DrToddLee @InfectiousDz @TogetherTrial https://t.co/m5CyCWuk0P
@Tatademurcia предполагаю, что они, для профилактики, вот это употребляют: https://t.co/A0kq1cRbG2
@leandrotessler @binerighetti https://t.co/1v01FMv723
@leandrotessler @binerighetti https://t.co/1v01FMv723
@leandrotessler @binerighetti Esse é o trial inicial https://t.co/1v01FMv723
@PetrLudwig Pište o novém způsobu léčby coronaviru, o kterém se málo píše: https://t.co/c2oLIFJpNG V Česku zatím v dávce 12 000, neregistrovaný lék...
https://t.co/wWdWHK0WJi
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 - https://t.co/oj1z87YYw2 https://t.co/i58swHBHgC
RT @lazyneocortex: уже писала, что в США больше года, в лечении ковида, используют моноклональные антитела. помните как Трамп болел 1 день…
RT @MDaware: @JSegor @MonicaGandhi9 we do know that. ARR from mAbs is on the order of 3-9%, vs something like 90% for vaccines and, again,…
@JSegor @MonicaGandhi9 we do know that. ARR from mAbs is on the order of 3-9%, vs something like 90% for vaccines and, again, mAbs don't protect those around you https://t.co/daQ16wi9AX https://t.co/W5mpmKm8FL https://t.co/2HKGcz3pKa
уже писала, что в США больше года, в лечении ковида, используют моноклональные антитела. помните как Трамп болел 1 день? вот! сейчас ученые утверждают, что коктейль REGEN-COV можно использовать для профилактики. подробней об исследовании https://t.co/A0kq1cRbG2
From this: https://t.co/NoLA5xVWbY it looks like the research was done before vaxx were in place so I assume the findings are from a nonvaxxed sample. Again, wondering if this also holds for a vaxxed sample.
Regeneron desenvolveu o coquetel de Ac neutralizantes (casirivimab e imdevimab) contra epítopos da proteína S-spike, retendo capacidade de ação in vitro contra todas as variantes de preocupação até o momento. O estudo de fase II foi publicado em dez/2020: https://t.co/8WHtZWIckj
@KTVB https://t.co/sxCEOipu5I
@CMichaelGibson Do they even work in vaccinated patients? L: nonhospitalized patients https://t.co/RLvfjsjFUp R: hospitalized patients https://t.co/0er7HWsv5G https://t.co/1HV78xG8WD
@DrSuperSalty That may make some sense https://t.co/RLvfjsjFUp https://t.co/Unkqaokqfl
Monoclonal Antibodies - What you NEED to know! https://t.co/EIy4Z69Wyd via @YouTube
RT @zpyarom: מחקרים על הטיפול: https://t.co/RoCgwNePmu וגם https://t.co/Mwhi2EpmAW למי שרוצה לחפש מידע נוסף באנגלית, הביטוי הוא monoclo…
מחקרים על הטיפול: https://t.co/RoCgwNePmu וגם https://t.co/Mwhi2EpmAW למי שרוצה לחפש מידע נוסף באנגלית, הביטוי הוא monoclonal antibodies, או בקיצור MAbs.
RT @edgarvlermamd: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #Visu…
RT @edgarvlermamd: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #Visu…
RT @edgarvlermamd: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #Visu…
RT @edgarvlermamd: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #Visu…
RT @edgarvlermamd: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #Visu…
RT @edgarvlermamd: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #Visu…
RT @edgarvlermamd: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #Visu…
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 ca. 2021 from @NEJM #Nephpearls #NephJC #VisualAbstract by @hellokidneyMD
Sub Q Regeneron https://t.co/VCz2UFINaA
https://t.co/wuqqCNZWd8
Monoclonal Antibodies - What you NEED to know! https://t.co/1Q4T56gOoI via @YouTube
https://t.co/7sWE2CTeNR
Monoclonal Antibodies - What you NEED to know! https://t.co/ccVOuVZ6RR via @YouTube
We prospectively pursued a “cocktail” approach because of previous experience with the emergence of treatment-resistant mutant virus when a single antibody, suptavumab, was used to target respiratory syncytial virus. https://t.co/LXqX9VcmkT
Monoclonal Antibodies - What you NEED to know! https://t.co/yTHi7fsJef via @YouTube
Monoclonal Antibodies - What you NEED to know! https://t.co/4NzN4i2OgH via @YouTube
Monoclonal Antibodies - What you NEED to know! https://t.co/LrXrnV9S9G via @YouTube
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/c26YTzXfwz
Monoclonal Antibodies - What you NEED to know! https://t.co/blGuJ7P4bw via @YouTube
#monoclonal #antibody @Regeneron #Casirivimab/#imdevimab, @EliLillyCo #Bamlanivimab/#etesevimab, @GSK #Sotrovimab #Covid_19 reduce: eg 71% hospitalisations, 70% deaths, 4 days recovery time. For #post-#exposure #prophylaxis & #early #treatment. Vaxx also. https://t.co/0zsFMXwcGL
Monoclonal Antibodies - What you NEED to know! https://t.co/HUpf9g886C via @YouTube
@AbeV4U @Patchemup1 @EcmoNinja Nah look at the trials themselves. They get the percentage from a difference in 3 vs. 6 “medically attended visits” that they don’t describe as Covid-related or not between treatment and placebo groups. Judge for yourself: https://t.co/RcSEfUMFHL
3.SARS-CoV-2変異株の一部はワクチンや回復期血清、モノクローナル抗体に対する感受性低下を示して*おり、すでにモノクローナル抗体の併用*などが行われています。 https://t.co/suKBwWhq9S https://t.co/2K4w0MeiWQ https://t.co/d7xfX17WIF https://t.co/D1qDBYcQos https://t.co/NOx6vLoTle
加えてSARS-CoV-2感染者の内因性免疫応答の多くは感染に対して有効に働く*という報告もあり、職員においてbamlanivimabが偽薬を上回る有効性を示されなかった本試験の結果と一致しています。 https://t.co/NOx6vLoTle
#057 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 N Engl J Med 2021;384:238-51.
@NPR He took Regeneron’s antibody cocktail. Hardly unproven. https://t.co/eT3WD1grKC
RT @DrHirschfield: An outpatient study measuring viral load reduction, a subset showed statistical sig reduction of viral load. Co-endpoint…
@Ron_Nirenberg @UnivHealthSA @BaptistHealthSA @SouthTexasMed @bcms_org when will healthcare providers proactively offer monoclonal antibodies to #COVID patients early in their illness ? Numerous studies indicate these drugs can reduce hospitalizations https://t.co/YOdkLn1Bxb
An outpatient study measuring viral load reduction, a subset showed statistical sig reduction of viral load. Co-endpoint is proportion of at least one medically attended visit. This study did not determine clinical benefit. https://t.co/cc7roMx20u https://t.co/eilxawXM7v
@Skidancer2 @RichSpence10 @gartmartin9 @GovRonDeSantis Maybe follow the science? https://t.co/c6Co2geMQk
@gartmartin9 @GovRonDeSantis I thought you were supposed to follow the science? ☕️
RT @hichachu: 文献10 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. Weinreich DM et al N Engl J Med. 2021 Jan 21;…
RT @hichachu: 文献10 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. Weinreich DM et al N Engl J Med. 2021 Jan 21;…
RT @hichachu: 文献10 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. Weinreich DM et al N Engl J Med. 2021 Jan 21;…
RT @hichachu: 文献10 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. Weinreich DM et al N Engl J Med. 2021 Jan 21;…
RT @hichachu: 文献10 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. Weinreich DM et al N Engl J Med. 2021 Jan 21;…
文献10 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. Weinreich DM et al N Engl J Med. 2021 Jan 21;384:238-251 https://t.co/UTVlFLKle0 抗体カクテルはウイルス量を減らし免疫応答がまだ開始されていない患者やベースラインでウイルス量が多い患者に大きな効果
https://t.co/q5yvPifVqU
RT @carpe_diem0820: COVID-19患者のうち、免疫反応がまだ得られていない患者、あるいはウイルス負荷が高い患者では、Regeneron社のモノクローナル抗体カシリビマブとイムデビマブによる治療がウイルス量低減に効果 REGN-COV2, a Neutra…
RT @DaveLeeERMD: Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated w…
RT @DaveLeeERMD: Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated w…
RT @DaveLeeERMD: Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated w…
RT @DaveLeeERMD: Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated w…
RT @DaveLeeERMD: Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated w…
@MrSirUgly But it appears to be a little like Tamiflu: you probably need to get it into you soon after infection ... "patients whose immune response had not yet been initiated" https://t.co/UZLJoNOOsb
@tiakiki246 @GovRonDeSantis Really? https://t.co/eT3WD1grKC
RT @DaveLeeERMD: Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated w…
RT @DaveLeeERMD: Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated w…
Here’s what the outpatient studies of mAbs for COVID-19 showed. While viral load decreased faster among patients treated with mAbs, viral load also dropped significantly by 7 days in both study arms. Viral load appears to be highest at symptom onset. https://t.co/vIKJvz7XjA
@GrimBeholder על תשלובת משובטת של נוגדנים במתן פלסמה הם לא שמעו או שמשרד המוות לא יידעם . הצלת חיים לא מעניינם. https://t.co/txP7hp9PMr
@josiegirl62 @ProfPCDoherty Trump got 8 grams of REGN-COV2 but that'd probably cost us about US$6,500 right now ... and a bit like Tamiflu it seems that REGN-COV2 works best only early in the infection: https://t.co/OGHU8YXf0H.
抗体カクテルがよくわかっていなかったのでちょっと調べた。ドラッグデザインとしては耐性株の出現抑制がポイントなのね。分かりやすかった。 https://t.co/qGCffYuDBX https://t.co/pA4B93AVgL
@reserved_word @ImNotOwned Regeneron's clinical trial is in only 275 subjects lol Pfizer's EUA was supported by a study involving 43,548 subjects https://t.co/GsyqbVThRK https://t.co/YF2T6ClgUQ
RT @jrarribas: Great discussion @DrBike7. If all is "association" why in the AR0-CORONA RCT https://t.co/NRq4xjHPYI there is a significant…
"Patients who were positive for any one of these antibodies [IgA anti-S1 domain of spike protein, IgG anti-S1 domain of spike protein, and IgG anti-nucleocapsid protein] were designated as serum antibody–positive" https://t.co/RLvfjs252R https://t.co/Z7Co2w1ut2
Great discussion @DrBike7. If all is "association" why in the AR0-CORONA RCT https://t.co/NRq4xjHPYI there is a significant difference in favor of TDF for viral clearance of 0.8 logs @ day 7?. This is similar to what mAbs do in outpatients: 10.1056/NEJMoa2035002 (−0.56 logs) https://t.co/Ugw6n0CJyf
RT @sgoto4: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/zdS9Ur40LI 抗体カクテルってこんなかんだね。
@minnesorta @ShohamTxID @TheRickWilson https://t.co/wWdWHK0WJi https://t.co/FBpNCMtnpk
https://t.co/wWdWHK0WJi https://t.co/hev7XgiJ8E
RT @sgoto4: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/zdS9Ur40LI 抗体カクテルってこんなかんだね。
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/zdS9Ur40LI 抗体カクテルってこんなかんだね。
@carterdotmusic Ok https://t.co/rvuhDv3qBC
Tell me @kerpen how these studies support the use of the mAb cocktail? Point to the confidence interval for a clinically meaningful endpoint that seals the deal. https://t.co/FWIZ1rCIzV https://t.co/tF2cTvuznY
@DirkWeezil @Moreskyplease @GovRonDeSantis Outpatient setting is also allowed https://t.co/eT3WD1grKC
@bluewave_elaine @GovRonDeSantis Who says the vaccines aren’t? The data for Regeneron’s antibodies are published. Free to read. https://t.co/EXIOVUx9k1
@NerdPyle @GovRonDeSantis The studies are published whether it works or not. Free to read. Stop spreading misinformation. https://t.co/EXIOVUx9k1
@OttoTopci @GovRonDeSantis 1. No. Read the study https://t.co/EXIOVUx9k1 2. So? 3. Not true at all. No antibodies are made using fetal tissue of any kind. Stop spreading misinformation.
@Bondad30360 @DrEllenEaton The mAbs are likely the best outpatient treatment, but they've not yet been shown to decrease mortality. https://t.co/zNo8XOQmU9
@NerdPyle @RandPaul The efficacy: https://t.co/eT3WD1grKC The cost: https://t.co/z9f02sU08P Stop lying. https://t.co/cx61VHGu3Q
@GeneralBitch @NerdPyle @RandPaul Before CoVid infection? Really? https://t.co/eT3WD1grKC
@CarolForden @thehowie @GovRonDeSantis Ok let's take a dive into the actual data from the studies. Here's the first two that come up when you search regeneron studies. Both support it's efficacy with similar side effects to placebo. This is what the actual data says. https://t.co/fbxYhOf8Z9 https://t.co/i0ltQp8wj0
@CathyNotToday @CarolForden @thehowie @GovRonDeSantis Upon actual investigation, the first two studies I found concluded Regeneron to reduce viral load and have the same side effects as the placebo. Here's one from the New England Journal of Medicine just so you don't think I'm kidding. https://t.co/fbxYhOf8Z9
@elise_oisen @Missy04924393 @mmpadellan You're arguing with a scientist, just saying. They have done it in both. Their EUA is for what was mentioned above. https://t.co/LHEilyQBs2
@notRaptorGuy @mmpadellan https://t.co/KJ12kXyAAY https://t.co/87GkIXZMkg https://t.co/Cd8wFgzp62 https://t.co/jutkIKXTy4 https://t.co/LHEilyQBs2 https://t.co/PEoIgUdlK2
@WalterS50823302 @Dafkagirl @WUTangKids @OneFreshPillow Like the New England Journal of Medicine is a cult? https://t.co/qqSMKKdmOb
@upshaw_stacy Atleast 60 days or longer? monoclonals they tend to stick around. doi:10.1056/NEJMoa2035002 Even by day 30 still has significant serum levels. So longer you wait the better for spike mrna based vaccines to elicit a immune response. Will be a booster in your situation anyways.
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/6XRd4fj6Kl
@Fla_Pol @GovRonDeSantis @AGGancarski https://t.co/molyB9zt8y
@SamAtallahMD @JoeBiden @GovRonDeSantis @AnnaForFlorida @meganranney @cnnbrk @jeremyfaust @AtulGroverMD Are y’all using this? https://t.co/molyB9zt8y
@orlandosentinel Are y’all offering this (or not yet), @orlandohealth and @AdventHealth? https://t.co/molyB9zt8y
I like how Regeneron is trying to sell that their antibody cocktail decreases death among those already infected when their article says the opposite (read the discussion) https://t.co/R92EfdGTLV #medicine #healthcare #residency #USMLE #medschool #doctor #MCCQE1 #COVID19
@RWMaloneMD what happens if you’re given REGN-COV2 if you’ve had the pfizer vaccine?? https://t.co/RZdrW1vCnU can anyone provide feedback?
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
RT @Katsumata_Nori: 新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていま…
新型コロナに対するカクテル療法の最初の論文はこちらです。New England Journal of Medicineという世界最高峰の医学誌に載っています。医学界の金メダルです。残念ながら日本はまだ新型コロナ研究では金メダルを取っていません。https://t.co/lAMZeviB2U
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
RT @influenzer3: →抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, i…
→抗体カクテル製剤の抗ウイルス効果は確実です。 今後の位置づけとしては、入院ハイリスク患者への早期投与になるのかと思います。 RDVにとってかわる?? REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/K3bNhCZxdp
RT @tyabu7973: モノクローナル抗体製剤(イムデビマブ/カシリビマブ)が話題だけど、Pubmedで調べてもRCTは以下のNEJM1件のみ。 ウイルス量をアウトカムにしたRCT(n=275)で、外来患者のウイルス量が減ったよというもの しかもそれを入院で使う? h…
RT @shams_z: Some important papers on Ab Cocktails. 1. https://t.co/acPVCl3MZw 2. https://t.co/NfAXTia2lJ 3. https://t.co/BDdSskdAZF 4. ht…
RT @epidatum: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 REGN-COV2 antibody cocktail reduced viral load, w…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @Vannyamoto: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 - PubMed 中外製薬の中和抗体を検証した臨床試験 https://t.co/Ci4xOEw…
RT @tyabu7973: モノクローナル抗体製剤(イムデビマブ/カシリビマブ)が話題だけど、Pubmedで調べてもRCTは以下のNEJM1件のみ。 ウイルス量をアウトカムにしたRCT(n=275)で、外来患者のウイルス量が減ったよというもの しかもそれを入院で使う? h…
RT @tyabu7973: モノクローナル抗体製剤(イムデビマブ/カシリビマブ)が話題だけど、Pubmedで調べてもRCTは以下のNEJM1件のみ。 ウイルス量をアウトカムにしたRCT(n=275)で、外来患者のウイルス量が減ったよというもの しかもそれを入院で使う? h…
モノクローナル抗体製剤(イムデビマブ/カシリビマブ)が話題だけど、Pubmedで調べてもRCTは以下のNEJM1件のみ。 ウイルス量をアウトカムにしたRCT(n=275)で、外来患者のウイルス量が減ったよというもの しかもそれを入院で使う? https://t.co/EFFQ0p5HOY
RT @Vannyamoto: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 - PubMed 中外製薬の中和抗体を検証した臨床試験 https://t.co/Ci4xOEw…
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 - PubMed 中外製薬の中和抗体を検証した臨床試験 https://t.co/Ci4xOEwxct
"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19" #中外製薬 #Regeneron / “カシリビマブ+イムデビマブ” https://t.co/IXT7LajMEi
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/CQOXIQ8Cty
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/44KG2D69e2
@NashVolGuy @ScottAdamsSays @AndreasShrugged >>There are no other drugs for Covid during the timeframe<< https://t.co/NtgU1VU92Q https://t.co/Ly5z3GOxKX
@barronsonline A new concept for treating COVID patients. AstraZeneca is trying it as a preventative, I guess. Their first attempt did not work but others are working on it too. e.g. Regeneron. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@ndtvfeed In simpler terms: A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@Reuters_Health In simpler terms: A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@TimesNow In simpler terms: A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@rapplerdotcom In simpler terms: A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@kakape In simpler language: A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@livemint This Cocktail is for TREATMENT no prevention. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@japantimes In plain English: A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@TimesLIVE A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@EconomicTimes A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@livemint A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@Reuters_Health A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Regeneron is doing better, apparently. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
A new concept for treating COVID patients. AstraZeneca's first attempt did not work but others are working on it too. Might take a year or two. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@KamilKaramali OK, Kamil, I want a song about this now REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/2YQNaprueJ
@MkingMaria @CTVNews @PHE_uk Here is an article about the research on Antibody Cocktail to treat COVID patients I guess it's not a preventative but a treatment A bit complicated for my non-scientist brain "REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19" https://t.co/2YQNaprueJ
RT @shams_z: Some important papers on Ab Cocktails. 1. https://t.co/acPVCl3MZw 2. https://t.co/NfAXTia2lJ 3. https://t.co/BDdSskdAZF 4. ht…
RT @shams_z: Some important papers on Ab Cocktails. 1. https://t.co/acPVCl3MZw 2. https://t.co/NfAXTia2lJ 3. https://t.co/BDdSskdAZF 4. ht…
@fgilc @boticariors De momento tendríamos el plasma hiperinmune... quién sabe si la colchicina (COLCORONA trial) y poco más porque remdesivir no tiene indicación hasta más avanzado el caso. Ya era prometedor el análisis intermedio con disminución de la carga viral https://t.co/5mbsXrAxrk
@ferbotto @ArgentinoHuman @PabloRichly Considering "REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19" and "SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19", n=650 of PREPARE-IT 2 is fairly significant. Would you consider to announce its interim result?
https://t.co/YLY8SivDuf
@debe the outcomes are those described in trials (human mind is not able to understand if an open label treatment is effective or not; it is only able to introduce biases
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/NtWnJDP7Gu
In this study, in @NEJM, we examine REGN-COV2: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/9K4kG2EGoa
2 leading pharma companies, Regeneration and Eli Lilly on the race to develop treatment & prophylaxis for COVID patients. Both are neutralizing antibodies or a cocktail of 2. Read up on the results of REGN-CoV2 and LY-CoV555 NEJM: https://t.co/4Rhx1T8oJr https://t.co/YactzdSArT
@ZDFheute Zugehöriger Artikel, steht im Internet: "REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19". Zumindest Erfahrungen mit wissenschaftlichen Artikel im medizinischen Bereich sind m.E. für ein Verständnis dringend erforderlich.
@ZDFheute Originalarbeit: "REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19". Lesenswert. Interessant wäre was Virologen davon halten."Further studies, including the continuing phase 3 portion of this trial, are needed to confirm these effects."
@Fischblog Es gibt eine Interimsanalyse. Leicht erkrankte, ambulante Patienten. Reduktion der Viruslast zwar statistisch signifikant aber auch nicht durchschlagend. Gibt's was anderes? https://t.co/AYcC2VWC9Z
#ARTÍCULO : REGN-COV2, un cóctel de anticuerpos neutralizantes, en pacientes ambulatorios con COVID-19. Descúbrelo en: https://t.co/3IPoEknuV7 O en: https://t.co/gzjRhMwbcm https://t.co/UMA5v98Ygg
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/zyDurMku1e
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/gagrMJKLx1
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/gFEi6si9Ax
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
@CJEllieson @ernestorr Gran hilo Ernesto!. Lo que hay publicado son los resultados del IA de REGN-COV2, no hablan de valor p solo mencionan el IC. Trump recibió tratamiento en Octubre y la FDA recién autorizó el uso (de emergencia) en Noviembre. https://t.co/eP0ht6viB5
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @kharaguchi: https://t.co/LhSUpBXoJ3 「REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19」 2020/12
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
https://t.co/LhSUpBXoJ3 「REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19」 2020/12
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
RT @influenzer3: 2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19…
2種のモノクローナル抗体カクテル製剤のREGN-COV2の報告です。 簡単にまとめておきます。 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 https://t.co/znEhmakdeF
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/pqQtXateoz
4/ Chen https://t.co/tiNMeqYXDi Weinreich https://t.co/59w4KHb3dx https://t.co/IerFvVJXOh
@sotostips @YpYgGR @PrimeministerGR https://t.co/X1gUeKY07c REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM https://t.co/iVPyTgy3eO
@VirusesImmunity @carolilucas @sneakyvirus1 This research gives lot of sense to the REGN-CoV2 results of dual antibody (Ab) to inhibit #SARSCoV2 Phase 2 trial: benefits in those cases with Ab (-) and higher levels of viral load. Both measures need to select patients @Regeneron @NEJM https://t.co/HJTSg0ToR0
Trending on PubMed: REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. https://t.co/IrKJq6pGSA
https://www.nejm.org/doi/full/10.1056/NEJMoa2035002
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with #COVID19 REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. https://t.co/OZGhtsjYU7 https://t.co/81QknjgZNe
中和抗体カクテル療法のRCT中間解析結果。NEJM。 ウイルス量は減りそうですね。最終解析が楽しみです。 それにしても、、 海外ではよくこの速度でできますね
An interim analysis of the ongoing trial for the antibody cocktail REGN-COV2 among non-hospitalized COVID-19 patients found a larger difference in viral loads among patients in treatment group compared to placebo group. https://t.co/MlcexqUzzH
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
RT @EricTopol: The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for…
The #SARSCoV2 dual antibody(Ab) @Regeneron Phase 2 report for outpatient covid @NEJM today —Most benefit in viral load⬇️ for people w/o native Ab response —Time of symptom onset does not correlate w/ Ab response https://t.co/itwnZp2GzZ https://t.co/JOfiJyQgI4